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Abstract
Background: Today, nonalcoholic fatty liver disease (NAFLD) has become a major health problem owing to its high prevalence.
Literature evidence about regression of NAFLD are not as high as its development or progression.
Objectives: This cohort study was conducted to reveal the factors influencing the regression of the NAFLD.
Methods: A population-based study conducted in Shiraz, Iran. Adults older than 18 years were recruited by multistage randomized
sampling in 2012, and then in 2017. Demographic, anthropometric, nutritional, and medical characteristics of each interviewee
were entered into a valid and reliable questionnaire. Interviewees were categorized into three groups according to the changing of
their NAFLD status between two stages of this study; no change, regressed and progressed.
Results: Of the 537 participants, 163 (30.3%) showed regression of their NAFLD compared to 93 (17.3%) that their NAFLD was pro-
gressed. Multinomial regression showed that each unit of decrease in BMI (∆ BMI= -1 kg/m2) augmented the relative risk (RR) of
improvement of NAFLD by 13.3% (RR: 0.867; 95% CI: 0.776 - 0.969; P = 0.012) and reduced the relative risk of NAFLD deterioration by
14.3% (RR: 1.143; 95% CI: 1.009 - 1.294; P = 0.035).
Conclusions: A significant portion of patients showed regression of their NAFLD by decreasing their BMI. Therefore, BMI as a mod-
ifiable variable should be regarded in the management of NAFLD patients.
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1. Background
As a metabolic disorder, nonalcoholic fatty liver dis-
ease (NAFLD) is characterized by excessive triglyceride (TG)
accumulation in hepatocytes in the absence of excessive al-
cohol consumption (1, 2). Today, NAFLD has become a ma-
jor health problem owing to its high prevalence and that
it augments the chances of progression to liver cirrhosis
and liver cancer, and increased the risk of cancer and car-
diovascular diseases (3). Current prevalence of NAFLD is es-
timated to be 24% - 42% in the western countries and 5% -
40% in Asian countries (2). A systematic review estimated
the prevalence of NAFLD in Iran as 33.9% (95% CI: 26.4 - 41.5)
(4). Furthermore, Lankarani et al. showed that the preva-
lence of the disease is around 21.5% in Shiraz, southern Iran
(5). Studies showed that lifestyle, environment, age, gen-
der, body mass index (BMI), visceral adiposity, genetic pre-
disposition and metabolic factors have crucial roles in the
incidence of NAFLD (2, 6). Diabetes type 2 and smoking
are also other relevant predictors of NAFLD occurrence (7).
Different studies assessed the risk factors and predictors
of NAFLD, and the expectation is that changing the possi-
ble risk factors would affect the progression of the disease.
However, at the time of our literature review, studies eval-
uating regression and progression of NAFLD concurrently
through a single longitudinal study are rare; and evidence
about regression of NAFLD are not as high as its develop-
ment or progression.
2. Objectives
This cohort study was conducted to reveal the factors
influencing the regression of the NAFLD.
3. Methods
3.1. Study Population
The present cohort research was carried out in Shi-
raz, a major metropolitan city in southern Iran. A multi-
stage proportional and cluster random sampling, based on
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homes’ postal codes was used. According to seven postal
districts of Shiraz, we divided the needed sample size pro-
portionally among these districts. Then from each of the
districts, the needed sample size was selected through ran-
dom sampling from listed postal codes. Each of the seven
postal code districts was considered as a cluster and one
person at least 18 years old was selected randomly from
each house. The exclusion criteria were being non-Iranian,
being pregnant, or having delivered within the previous
six months. Over a 10-month period (from November 2012
to September 2013), 844 participants took part in the first
phase of this study. The main aim of the cohort study was
to assess non-communicable diseases in Shiraz, Iran. The
cohort protocol was specifically explained in the Lankarani
et al. study (5). Four years later (2017), the second phase of
the study was carried out, where 554 out of the 844 subjects
participated, and all steps of study were repeated for them.
According to the fatty liver stages in the two phases, sub-
jects were classified into 3 groups: (1) Unchanged group,
including normal or those with mild NAFLD grade, in both
phases. Those who had moderate or severe NAFLD grade in
both phases, were excluded due to their limited numbers.
(2) Regressed group, including those who suffered from
certain stages of fatty liver in phase 1, yet their status had
improved with lower fatty liver stages in the second phase.
(3) Progressed group, included participants who got worse
based on their fatty liver stages.
3.2. Measurements
At the baseline of the study, a questionnaire including
demographic, and social characteristics was completed
through a face to face interview. The information was col-
lected based on the marital status (single/married), edu-
cation (lower/higher than 12 years), job status (employed/
unemployed), and tobacco use at the baseline. Dietary in-
take was evaluated in both phases, using a 168-item food
frequency questionnaire (FFQ) (8) which assessed food in-
take over the previous year and analyzed via Nutritionist-4
software modified for Persian food by National Nutrition
and Food Technology Research Institute. A physically ac-
tive person was defined as an individual who has an ac-
tivity for at least 150 to 300 minutes a week of moderate-
intensity, or 75 to 150 minutes a week of vigorous-intensity,
or an equivalent combination of moderate- and vigorous-
intensity (9). Height was measured through the use of a
tape measure to the nearest 0.1 cm and weight was mea-
sured, with a measurement accuracy of 0.1 kg, while wear-
ing light clothes. The BMI was calculated as weight/height2
(kg/m2). Waist circumference (WC) was measured by mea-
suring the distance around the narrowest area of the waist
between the lowest rib and iliac crest and above the um-
bilicus using a non-stretchable tape measure (10). Fasting
blood sugar (FBS), serum levels of TG, low-density lipopro-
tein (LDL), and high-density lipoprotein (HDL) and systolic
blood pressure (SBP) and diastolic blood pressure (DBP)-
according to the WHO criteria (11)- were measured for each
person in both phases. NAFLD was detected by abdom-
inal ultrasonography which revealed an increase in the
echogenicity of liver parenchyma and a decrease in the
echogenicity of portal vein or diaphragm (2). For preven-
tion of inter-observer error, abdominal ultrasonography
was done by the same radiologist and the same protocol.
Consultation with internal medicine specialist was con-
ducted for participants who were not under clinical follow
up or who had not been visited previously by internists.
After examination, the study population were informed
about their fatty liver status.
3.3. Statistical Analysis
The data were expressed as median percentage.
Amount of differences between the two phases of study
(delta: ∆) were calculated for quantitative variables, such
as BMI (kg/m2), WC (cm), calories (Kcal), protein (gr), fat
(gr) and carbohydrate (gr) intakes, FBS, TG, LDL, and HDL.
Kruskal-Wallis and chi-squared tests were used as univari-
ble analysis. In the next step, variables such as age,∆-BMI,
∆-WC, ∆-calories and carbohydrate intake, ∆-FBS, ∆-TG,
∆-LDL and ∆-SBP, and also marital status, education, job
status, with p-value less than 0.2 in univariable analysis,
were entered into the multi-nominal logistic regression
analysis to examine the relative risk of regression and
progression of NAFLD, and no change group was consid-
ered as reference group. Collinearity among variables was
assessed using variance inflation factor (VIF) before multi-
variate analysis and no collinearity was observed (VIF = 1).
The IBM SPSS statistics (version 20-IBM corporation-USA)
and Nutritionist-4 (version 3.5.2, N-Squared Computing
and First DataBank of The Hearst Corporation-USA) were
used to do statistical and food intake analysis, respectively.
4. Results
Out of 844 participants in the first stage, 554 (65.6%)
attended in the second stage of this study. After exclud-
ing participants who had moderate (n = 13) or severe (n
= 4) NAFLD in both phases, analysis was done on 537 par-
ticipants, of whom 163 (30.3%) showed regression of their
NAFLD compared to 93 (17.3%) that developed NAFLD or
their NAFLD had progressed. The median age of partici-
pants in the second stage was 44 years and 308 (57.3%) were
female. In the second stage, among all participants, the
median of BMI was 26.0 kg/m2. Prevalence of normal, mild,
moderate, and severe grades of NAFLD was 53.9%, 23.6%, 16%,
6.5%, in the first and 54.0%, 35.7%, 8.5%, 0.9% in the second
phases of study, respectively. Furthermore, history of hy-
perlipidemia, hypertension, diabetes, overweightness and
obesity was 19.6%, 11.1%, 7.0%, 42.2%, 19.6%, in the first and
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in 25.1%, 22.2%, 10.4%, 42.7%, 18.5% in the second phases of
study, respectively. Characteristics of participants in case
of demographic, social, anthropometric and medical sta-
tus were shown in Table 1.
There were significant differences between regressed,
progressed and unchanged groups in terms of partici-
pants’ age, marital status, and education, and∆-daily calo-
ries and carbohydrate intakes, and value of BMI, WC, FBS,
and serum TG, and LDL. Analysis showed that∆-daily calo-
ries intake (P = 0.02), ∆-daily carbohydrate intake (P =
0.01),∆-BMI (P < 0.001),∆-WC (P < 0.001),∆-FBS (P = 0.01),
∆-TG (P = 0.001), and ∆-LDL (P = 0.02) were significantly
lower in regressed than progressed groups. Moreover, par-
ticipants who were married (P = 0.01), and had an educa-
tion of lower than 12 years (P = 0.01) were significantly more
frequent in regressed compared to the progressed group.
Results of multi-nominal regression, were shown in the Ta-
ble 2. Every one unit decrease in difference of BMI (BMI in
phase 2 minus BMI in phase 1), increased the relative risk of
improvement by 13.3 percent (RR: 0.86; 95% CI: 0.77 - 0.96;
P = 0.01) and decreased the relative risk of deterioration of
the disease by 14.3% (RR: 1.14; 95% CI: 1.009 - 1.29; P = 0.03).
Age was also a significantly effective covariate in increasing
the relative risk of improvement, although it was not effec-
tive in progression of the disease. Trend of BMI Changes
in regressed, progressed and unchanged groups of NAFLD
was shown in Figure 1 and effect of∆-BMI on the incident
risk of regression and progression of NAFLD, was shown in
the Figure 2.
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Figure 1. Trend of median changes of BMI and standard error bars at the baseline
and follow up in regressed, progressed and unchanged groups of NAFLD patients
during four years of a cohort study in Shiraz, Iran
5. Discussion
In this cohort study, association of demographical, so-
cial, anthropometrical, dietary and medical factors with
the improvement or progression of NAFLD were assessed.
Based on the univariable analysis, variables such as age,∆-
daily calories intake,∆-daily carbohydrate intake,∆-BMI,
∆-WC,∆-FBS,∆-TG,∆-LDL,∆-SBP, marital status, and edu-
cation were associated with changing of NAFLD status.
5.1. Demographic and Social Risk Factors of NAFLD Regression
or Progression
Several studies found that age was associated directly
with NAFLD; with increasing age, the possibility of NAFLD
would be more (1, 2, 6), but these studies were mostly cross
sectional. Furthermore, there is an age-related increase
in visceral adiposity and muscles and liver fat deposition,
which is associated with NAFLD (12). In recent study, age
was a predictor of higher relative risk of regression. The
mean rank of age was significantly higher in the regression
group, suggesting that patients were more self-concern
than the first phase of the study by their age increased over
the time. However, analysis of our variables did not show
any association between physical activity and diet with re-
gression and progression of the disease. Factors such as
age-related metabolic changes can be considered in later
stages of the cohort.
Based on many studies, gender is another factor re-
lated to NAFLD, (1, 2) while, some studies reported no gen-
der differences among NAFLD cases (13). Similarly, in the
present study, there was no gender difference between the
regression and progression groups of NAFLD cases. We
also found that marital status and level of education var-
ied amongst the groups; where married participants and
those with education level less than 12 years showed more
relative risk of regression compared to the counterpart
groups. This finding is in opposition to another study that
showed those with lower education had a higher risk of
NAFLD (14). Lower education probably could be in line with
more physical activities, or lower income which would be
correlated with lower calorie intake or higher fiber intake
from vegetable and legumes as lower price source of food.
In line with other researches, tobacco usage was not differ-
ent among the groups of our study (14, 15). However, other
reports revealed that smoking was correlated with NAFLD
(12).
5.2. Biochemical Parameters AssociatedwithNAFLDRegression
or Progression
The values of ∆-FBS, ∆-TG, and ∆-LDL were signifi-
cantly lower in the regression group in comparison with
the progression group, showing that participants who had
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Table 1. Demographic, Social, Anthropometric and Medical History of the NAFLD Patients in a Cohort Study in Shiraz, Iran
Variables Regressed (N = 163) Progressed (N = 93) Unchanged (N = 281) P Value
Age, median (IQR), y 50 (43, 58) 40 (31, 49) 41 (29, 50) < 0.001
∆-Daily calories intake, median (IQR), Kcal 131.0 (-429.5, 497.0) 281.0 (-84.0,770.0) 125.0 (-241.1, 637.5) 0.02
∆-Daily protein intake, median (IQR), gr 6.7 (-12.7, 26.7) 3.6 (-16.8, 20.2) 3.4 (-12.9, 24.1) 0.34
∆-Daily fat intake, median (IQR), gr -15.1 (-27.7, 0.7) -19.8 (-39.0, -1.2) -18.5 (-32.3, -1.2) 0.22
∆-Daily carbohydrate intake, median (IQR), gr 52.1 (-23.5, 145.6) 92.8 (35.7, 172.8) 61.0 (-0.3, 156.6) 0.01
∆-BMI, median (IQR), kg/m2 -0.6 (-1.8, 0.7) 0.9 (-0.4, 2.2) 0.1 (-0.9, 1.4) < 0.001
∆-WC, median (IQR), cm 6.0 (2.0, 11.0) 10.0 (6.5, 15.0) 7.0 (3.0, 12.0) < 0.001
∆-FBS, median (IQR), mg/dL 2.0 (-11.5, 14.0) 8.0 (-1.0, 19.0) 5.0 (-4.0, 14.0) 0.01
∆-TG, median (IQR), mg/dL -23.0 (-68.0, 16.0) 1.0 (-32.0, 42.0) -8.0 (-38.0, 37.0) 0.001
∆-LDL, median (IQR), mg/dL -18.0 (-42.0, 8.0) -5.0 (-32.2, 22.2) -8.0 (-29.0, 13.0) 0.02
∆-HDL, median (IQR), mg/dL -3.0 (-14.0, 6.0) -3.0 (-11.0, 8.0) -3.0 (-12.0, 6.0) 0.81
∆-SBP, median (IQR) 0.0 (-8.0, 11.0) 0.0 (-9.0, 10.5) -1.0 (-10.8, 10.0) 0.13
∆-DBP11 , median (IQR) 1.0 (-7.0, 8.0) 2.0 (-3.0, 10.5) 2.0 (-4.0, 8.3) 0.43
Gender, No. (%)
Male 75 (32.8) 44 (19.2) 110 (48.0)
Female 88 (28.6) 49 (15.9) 171 (55.5) 0.22
Marital status, No. (%)
Married 154 (32.6) 80 (16.9) 239 (50.5)
Single 9 (14.1) 13 (20.3) 42 (65.6) 0.01
Education, No. (%)
≤ 12 years 49 (23.1) 43 (20.3) 120 (56.6)
> 12 years 114 (35.2) 50 (15.4) 160 (49.4) 0.01
Job status, No. (%)
Employed 48 (25.5) 35 (18.6) 105 (55.9)
Unemployed 115 (33.2) 58 (16.8) 173 (50.0) 0.18
Tobacco use, No. (%)
Yes 36 (36.0) 16 (16.0) 48 (48.0)
No 124 (28.8) 75 (17.4) 231 (53.7) 0.37
Physical activity, No. (%)
Yes 54 (26.5) 35 (17.2) 115 (56.4)
No 96 (32.1) 52 (17.4) 151 (50.5) 0.35
Abbreviations:∆, difference between two phases of cohort study (phase 2 - phase 1) ; BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL,
high-density lipoprotein; IQR, inter-quartile range; LDL, low-density lipoprotein; NAFLD, Non-alcoholic fatty liver disease; SBP, systolic blood pressure; TG, triglyceride;
WC, waist circumference.
followed medical recommendations had a better probabil-
ity for NAFLD regression. Other studies considered dyslipi-
demia, hypertension and type 2 diabetes as the risk fac-
tors for NAFLD (2, 6). In a Persian Guilan cohort, on 950
individuals, SBP, DBP, FBS and lipid profile such as TG, to-
tal cholesterol, and HDL were correlated with NAFLD. How-
ever, there was no correlation with LDL (16). In the van den
berg et al. study, patients with NAFLD had a higher preva-
lence of type 2 diabetes (1). Based on a report, blood glu-
cose was an independent variable of advanced NAFLD sta-
tus and severe fibrosis (17). In a cohort study of a healthy Ko-
rean population, NAFLD and its severity had independent
and strong association with incidence of diabetes (18). At
the baseline of the present study, 10.7% of the participants
with NAFLD had diabetes. Conversely, in the unchanged
group, the prevalence of diabetes was 4.3%, suggesting that
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Table 2. Multi-Nominal Regression Analysis of Factors Associated with Regression and Progression of NAFLD in a Cohort Study in Shiraz, Iran
Variables
Regressed vs. Unchanged Group Progressed vs. Unchanged Group
RR 95% CI P Value RR 95% CI P Value
Age 1.06 1.04 - 1.09 < 0.001 1.005 0.98 - 1.03 0.71
∆-BMI 0.86 0.77 - 0.96 0.01 1.14 1.009 - 1.29 0.03
∆-Daily calories intake 1.00 0.99 - 1.006 0.68 1.00 0.99 - 1.00 0.23
∆-Daily carbohydrate 1.003 0.99 - 1.006 0.10 1.001 0.99 - 1.005 0.73
∆-WC 1.004 0.97 - 1.03 0.80 1.03 0.99 - 1.07 0.05
∆-FBS 0.99 0.98 - 1.001 0.10 1.004 0.99 - 1.01 0.40
∆-TG 0.99 0.99 - 1.002 0.48 0.99 0.99 - 1.003 0.74
∆-LDL 0.99 0.99 - 1.003 0.26 0.99 0.99 - 1.005 0.69
∆-SBP 0.99 0.98 - 1.01 0.90 1.01 0.99 - 1.03 0.29
Marital status
Single (ref)
Married 1.19 0.49 - 2.58 0.68 1.29 0.57 - 2.88 0.53
Education
≤ 12 years (ref)
>12 years 0.78 0.47 - 1.27 0.32 1.05 0.60 - 1.84 0.85
Job status
Unemployed (ref)
Employed 1.51 0.89 - 2.58 0.12 1.26 0.70 - 2.28 0.43
Abbreviations:∆, difference between two phases (phase 2 - phase 1); BMI, body mass index; CI, confidence interval; FBS, Fasting blood glucose; LDL, low-density lipopro-
tein; NAFLD, non-alcoholic fatty liver disease; ref, reference; RR, relative risk; SBP, systolic blood pressure; TG, triglyceride; WC, waist circumference.
diabetes was a risk factor for NAFLD.
5.3. Dietary and Physical Activity Risk Factors Associated with
NAFLD Regression or Progression
As we concluded from univariable analysis, ∆-daily
calories and carbohydrate intake were significantly
higher in progressed than regressed or unchanged group.
Romero-Gomez et al. suggested that dietary habits and
physical activity (lifestyle changes), have to be the primary
line of treatment concerning NAFLD and nonalcoholic
steatohepatitis (NASH) (3). According to another study,
diet plays a major role in the development and progres-
sion of NAFLD (19). Low carbohydrate diet can reduce
liver fat for only a short period of time (20). However, in
the long run, reduction of liver fat seems to be a result
of weight-loss (21). Whether or not exercise has a direct
influence on liver fat is yet to be fully discussed (22, 23).
Habitual physical activity was negatively associated with
liver fat, independent of BMI, yet dependent on visceral
adiposity (24). Regarding the impact of lifestyle modifica-
tion on NAFLD, controversial recommendations were due
to differences in the studies’ design, namely, various forms
of lifestyle interventions with different diets and physical
activity regimens, absence of standardized endpoints, di-
verse phenotypes of NAFLD, different follow-ups together
with a relatively small number of patients included in the
earlier trials.
5.4. Anthropometric Risk Factors Correlated to the NAFLD Re-
gression or Progression
BMI was the main risk factors to influence the NAFLD
regression or progression in our study. The results showed
that BMI had the most effect on the regression and pro-
gression of NAFLD; the reduction in BMI increased the re-
gression of NAFLD and vice versa. However, increasing BMI
had a bit more effect on increasing the probability of pro-
gression of NAFLD than reduction of BMI in increasing rela-
tive risk of its regression. Although NAFLD and its more se-
vere form, NASH, might develop in non-obese patients, the
dominant portion of these diseases occurs in obese or over-
weight individuals (14). The BMI, WC, and weight-to-height
ratio were observed to be associated with NAFLD, with BMI
being a better index for diagnosing NAFLD (2). Closely asso-
ciated with NAFLD development and its progression, obe-
sity is a pro-inflammatory condition resulting in insulin
resistance (25). It was suggested that, weight reduction,
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Figure 2. Relative risk (RR) of regression (A) versus progression (B) of NAFLD status according to BMI changes (∆-BMI) through a four-year cohort study in Shiraz, Iran
with its clear dose-response association, is the most estab-
lished treatment for both NAFLD and NASH. In other word
the effect of weight loss on histological improvement of
liver was found to be dependent on the weight reduction
degree, regardless of the method employed to reach it (3).
Romero-Gomez, et al. had also showed that weight loss had
been further underlined in NASH patients, where weight
loss > 7% was related to a clinically meaningful regression
of disease status and weight reduction of≥ 10% was able to
ameliorate fibrosis by at least one stage (3) and resulted in
improvement of liver enzymes and histology (26). Further-
more, a modest 3 - 5 kg weight gain, regardless of baseline
BMI, predicted the development of NAFLD (27). In another
study on NASH patients, those with 10% (or more) loss of
the total body weight had observably higher rates of fibro-
sis regression (63% vs.9%) (28).
In western countries, visceral obesity was reported to
be associated with the pathogenesis of NAFLD, compared
with the overall obesity (29). Accordingly, WC was a well-
known surrogate marker of abdominal fat accumulation.
However, similar to Hu et al. study that was conducted
in East Asia (2), we found that BMI was superior to WC
and was a better index of NAFLD status. Fracanzani et al.
showed that there was a significant correlation between
hepatic steatosis and visceral adiposity, yet failed to show
that WC and NASH were correlated at multivariate analy-
sis (30). They indeed proposed that with the appearance of
NASH, visceral fat is no longer a significant determinant of
the degree of liver damage.
Using ultrasonography was the limitation of our study.
In NAFLD, the primary disease of interest is NASH as this
NAFLD phenotype carries the risk of hepatic fibrosis and
cirrhosis- Ultrasonography findings are unable to differen-
tiate whether nonalcoholic fatty liver or NASH is present.
Histopathological findings are excellent benchmarks for
the diagnosis of NAFLD; and liver elastography also was a
costly method which were not easily accessible to use in
our cohort study. Furthermore, Medication adherence was
self-reported which was a limitation in our study. As a rec-
ommendation, revealing the effect of treatments in partic-
ipants with decreased BMI, and its effect on regression of
NAFLD should be considered in the future studies. We also
suggest to compare groups with fixed severity of NAFLD
at the beginning and end of the cohort study with other
groups in the next researches. According to evidence of
obesity and development of NAFLD in children, follow-up
cohort on this age group is suggested.
5.5. Conclusions
BMI is the most important determinant of NAFLD re-
gression and progression. The reduction in BMI signifi-
cantly augments the probability of regression and reduces
the probability of the progression of NAFLD.
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